Next, we sought to assess whether ATM inhibition could enhance anti-Gal-9 therapy in the poorly immunogenic LLC murine lung cancer model 28 that is resistant to current immune checkpoint blockade 29. Here, LGALS9 is linked to lung carcinoma.